Article

AstraZeneca C.E.O. to Step Down

David Brennan, the chief executive of AstraZeneca, will step down on June 1 as the big British pharmaceutical company struggles with competition from makers of generic drugs and the failure of several drug development projects.

Mr. Brennan, 58, who has been in his post for six years, was under some pressure from shareholders to resign because of AstraZeneca’s performance.

Read the full story: http://hcp.lv/IhDj2O

Source: The New York Times

Related Videos
Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami Cancer Institute of Baptist Health South Florida
1 expert is featured in this series.
Ali Khawar
 Priscilla Tsondai, MD, MPH, International AIDS Society/CIPHER
Eileen Peng, PharmD, sitting for a video interview
ASCO Preview 2025
James Chalmers, MD
Gary Falcetano, PA-C, AE-C.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo